APROCITENTAN

Product IDORSIA PHARMACEUTICALS US INC
Total Payments
$77,374
Transactions
76
Doctors
8
Companies
1

Payment Trends by Year

Year Amount Transactions Doctors
2023 $77,374 76 8

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $49,881 8 64.5%
Travel and Lodging $25,865 26 33.4%
Food and Beverage $1,628 42 2.1%

Top Doctors Receiving Payments for APROCITENTAN

Doctor Specialty Location Total Records
, MD Cardiovascular Disease West Hollywood, CA $16,524 12
, MD Specialist New York, NY $12,861 12
, M.D Internal Medicine Ann Arbor, MI $11,060 11
, MD Internal Medicine Stanford, CA $10,277 8
, M.D Internal Medicine Reno, NV $8,987 10
, M.D Internal Medicine Chicago, IL $8,983 8
, MD Nephrology Philadelphia, PA $6,221 7
, M.D., S.M Internal Medicine New York, NY $2,460 8

About APROCITENTAN

APROCITENTAN is a product associated with $77,374 in payments to 8 healthcare providers, recorded across 76 transactions in the CMS Open Payments database. The primary manufacturer is IDORSIA PHARMACEUTICALS US INC.

Payment data is available from 2023 to 2023. In 2023, $77,374 was paid across 76 transactions to 8 doctors.

The most common payment nature for APROCITENTAN is "Consulting Fee" ($49,881, 64.5% of total).